Capital Research Global Investors
TEVA icon

Capital Research Global Investors’s Teva Pharmaceuticals TEVA Stock Holding History

Capital Research Global Investors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-82,644,367
Closed -$731M – 435
2023
Q1 		$731M Sell
82,644,367
-32,149,622
-28% -$318M 0.21% 104
2022
Q4 		$1.05B Sell
114,793,989
-2,396,339
-2% -$20.9M 0.32% 82
2022
Q3 		$946M Buy
117,190,328
+24,024,045
+26% +$212M 0.31% 83
2022
Q2 		$701M Sell
93,166,283
-38,999,232
-30% -$340M 0.22% 100
2022
Q1 		$1.24B Sell
132,165,515
-185,235
-0.1% -$1.55M 0.31% 78
2021
Q4 		$1.06B Buy
132,350,750
+13,474,099
+11% +$122M 0.23% 99
2021
Q3 		$1.16B Sell
118,876,651
-3,775,923
-3% -$35.4M 0.27% 87
2021
Q2 		$1.21B Sell
122,652,574
-6,040,649
-5% -$63.9M 0.28% 88
2021
Q1 		$1.49B Sell
128,693,223
-1,447,024
-1% -$16.6M 0.36% 67
2020
Q4 		$1.26B Buy
130,140,247
+32,778
+0% +$314K 0.33% 78
2020
Q3 		$1.17B Sell
130,107,469
-20,476
-0% -$217K 0.35% 66
2020
Q2 		$1.6B Buy
130,127,945
+37,144
+0% +$420K 0.51% 39
2020
Q1 		$1.17B Sell
130,090,801
-859,876
-0.7% -$8.81M 0.46% 54
2019
Q4 		$1.28B Buy
130,950,677
+21,250
+0% +$190K 0.38% 63
2019
Q3 		$901M Buy
130,929,427
+37,198
+0% +$285K 0.3% 81
2019
Q2 		$1.21B Buy
130,892,229
+2,700,837
+2% +$32.6M 0.38% 61
2019
Q1 		$2.01B Buy
128,191,392
+6,237,109
+5% +$110M 0.64% 42
2018
Q4 		$1.88B Buy
121,954,283
+3,105,683
+3% +$63.7M 0.66% 43
2018
Q3 		$2.56B Sell
118,848,600
-3,184,236
-3% -$73.9M 0.74% 34
2018
Q2 		$2.97B Buy
122,032,836
+363,631
+0.3% +$7.42M 0.81% 35
2018
Q1 		$2.08B Buy
121,669,205
+22,916,493
+23% +$447M 0.59% 48
2017
Q4 		$1.87B Buy
98,752,712
+28,656,135
+41% +$431M 0.55% 54
2017
Q3 		$1.23B Sell
70,096,577
-6,228,482
-8% -$140M 0.37% 69
2017
Q2 		$2.54B Buy
76,325,059
+9,260,426
+14% +$287M 0.79% 32
2017
Q1 		$2.15B Buy
67,064,633
+22,667,886
+51% +$774M 0.68% 42
2016
Q4 		$1.61B Buy
44,396,747
+23,520,998
+113% +$939M 0.52% 56
2016
Q3 		$960M Buy
20,875,749
+3,609,949
+21% +$188M 0.32% 79
2016
Q2 		$867M Buy
17,265,800
+5,722,500
+50% +$305M 0.3% 92
2016
Q1 		$618M Buy
11,543,300
+155,800
+1% +$9.14M 0.21% 122
2015
Q4 		$747M Buy
11,387,500
+7,675,500
+207% +$474M 0.26% 99
2015
Q3 		$210M Hold
3,712,000
– – 0.07% 219
2015
Q2 		$219M Sell
3,712,000
-5,518,700
-60% -$340M 0.07% 235
2015
Q1 		$575M Sell
9,230,700
-15,551,300
-63% -$904M 0.2% 126
2014
Q4 		$1.43B Sell
24,782,000
-6,410,152
-21% -$357M 0.48% 52
2014
Q3 		$1.68B Sell
31,192,152
-1,703,000
-5% -$90.2M 0.58% 45
2014
Q2 		$1.72B Sell
32,895,152
-10,492,148
-24% -$536M 0.6% 42
2014
Q1 		$2.29B Sell
43,387,300
-5,045,000
-10% -$233M 0.83% 27
2013
Q4 		$1.94B Sell
48,432,300
-10,634,616
-18% -$419M 0.72% 34
2013
Q3 		$2.23B Buy
59,066,916
+884,016
+2% +$34.5M 0.88% 25
2013
Q2 		$2.28B Buy
+58,182,900
New +$2.27B 0.97% 22

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Research Global Investors's TEVA Position: Q2 2023 in Review

Capital Research Global Investors sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 82,644,367 shares — an estimated $731M sold.

Capital Research Global Investors first reported a position in TEVA in Q2 2013 and held it in 40 quarters. The position peaked at $2.97B in Q2 2018. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • Capital Research Global Investors reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Capital Research Global Investors sold 82,644,367 Teva Pharmaceuticals shares in Q2 2023, an estimated $731M.
  • Capital Research Global Investors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 40 quarters.
  • Capital Research Global Investors's Teva Pharmaceuticals position peaked at $2.97B in Q2 2018.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Capital Research Global Investors's 13F filing for Q2 2023, filed 11 Aug 2023.